Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Open accessThe DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index; 37 of the 63 sources its claims cite were checked for support.
Abstract
Thyrotoxicosis is an adverse event associated with immune checkpoint inhibitors (ICPis) that occurs in 0.6 to 3.2% of treated patients, depending on ICPi class. Presentation usually consists of a biphasic thyroiditis with transient thyrotoxicosis and secondary hypothyroidism. ICPi-induced Graves’ disease (GD), due to the stimulating activity of TSH-receptor autoantibodies (TRAb), is extremely rare. The aim of this retrospective study was to describe the characteristics and evolution of GD during ICPi therapy. Five among 243 patients followed for ICPi-induced thyrotoxicosis showed TRAb positivity (2% of the cohort). GD occurred quickly after initiation of ICPis; its course was typical for two patients, with prolonged requirement for antithyroid drug treatment (ATD). The three other patients experienced biphasic thyroiditis with secondary hypothyroidism requiring long-term substitution. Three other patients had a diagnosis of GD before starting ICPis; they evolved toward hypothyroidism with early cessation of ATD and long-term substitution treatment during ICPi treatment. None developed significant Graves’ orbitopathy. ICPi treatment was not interrupted for thyroid dysfunction. In conclusion, GD is a rare, immune-related adverse event of ICPis with an unusual course and frequent evolution to biphasic thyroiditis. In the case of ICPi-induced thyrotoxicosis in the presence of TRAb, observing the spontaneous evolution and performing a scintigraphy are useful before starting ATD treatment. Pre-existing GD is not exacerbated by ICPis and tends to evolve towards hypothyroidism. ICPi treatment can be maintained with adequate biochemical surveillance.
Overview
CoChat Summary
TL;DR
In a retrospective Lyon cohort of 243 patients with ICPi-induced thyrotoxicosis, 5 (2%) had TRAb-positive induced Graves’ disease and 3 had pre-existing Graves’ disease. Induced GD often followed an atypical course, with 3/5 evolving to hypothyroidism, while pre-existing GD uniformly evolved to hypothyroidism; no severe hyperthyroidism or significant orbitopathy occurred and ICPi was maintained.
Key findings
- Among 243 patients referred for thyrotoxicosis during ICPi treatment, 5 (2%) had TRAb-positive ICPi-induced GD; 3 additional patients had pre-existing GD before starting ICPis.
- In induced GD, 2/5 had a typical Graves’ course requiring prolonged antithyroid drug treatment (about one year for patient 1; patient 2 was still on ATD after 6 months because tapering caused recurrence), while 3/5 had transient thyrotoxicosis and evolved to hypothyroidism requiring long-term substitution.
- All 3 patients with pre-existing GD developed secondary hypothyroidism with early ATD cessation and long-term levothyroxine; none developed irAE. None of the 8 patients developed significant Graves’ orbitopathy or severe hyperthyroidism, and ICPi treatment was not interrupted for thyroid dysfunction.
- The literature review found only nine reported cases of ICPi-induced Graves’ hyperthyroidism and seven of induced Graves’ orbitopathy, with one patient having both; all eight induced GD cases without orbitopathy had TRAb positivity and/or high iodine uptake, and only one evolved to spontaneous hypothyroidism.
Methods
- Retrospective descriptive cohort study with longitudinal follow-up at the University Hospital of Lyon, France, from December 2015 to December 2020, via the ImmuCare and Tox’imm networks; included adults with thyrotoxicosis diagnosed at pre-therapeutic screening or during ICPi treatment for any cancer and positive TRAb.
- Thyrotoxicosis was defined as low TSH (normal 0.4–4 mUI/L) with high FT4 (normal 12–22 pmol/L) and/or high FT3 (normal 3.1–6.8 pmol/L); TRAb positivity was >1.6 UI/L, TPOAb positivity >34 UI/mL; scintigraphy/ultrasound were used when required; secondary hypothyroidism was high TSH with low FT4/FT3 without thyroid treatment.
- The paper also reviews published cases of ICPi-induced Graves’ hyperthyroidism and orbitopathy (Table 3).
Limitations
- Stated: the series is small (5 induced GD, 3 pre-existing GD), retrospective, and from a single tertiary referral center; the authors state the 2% TRAb-positive prevalence is probably an overestimate because patients with mild thyrotoxicosis may not have been referred.
- Stated: TRAb bioassays could not be performed to distinguish stimulating from blocking antibodies, and no information was available on time to TRAb negativity in the induced GD patients.
- Evident from the text: there was no control group; ICPi regimens, cancer types, follow-up frequency, and scintigraphy timing were heterogeneous, and the literature comparison relies on case reports.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
19 Valid · 3 Not valid · 9 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Histological and morphological analysis can demonstrate different pathophysiological mechanisms between autoimmune and ICPi-induced thyrotoxicosis [26,27].”
§ Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) > 4. Discussion
What the sources say
- Not checked — no full text of the sourcecites [26] Torimoto K. Okada Y. Nakayamada S. Kubo S. Tanaka Y. Anti-PD-1 Antibody Therapy Induces Hashimoto’s Disease with an Increase in Peripheral Blood Follicular Helper T Cells Thyroid. 2017 27 1335 1336 10.1089/thy.2017.0062 28699391 source
- Partly supportedcites [27] Angell T.E. Min L. Wieczorek T.J. Hodi F.S. Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma Genes Dis. 2018 5 46 48 10.1016/j.gendis.2017.11.002 29619406 PMC5879785 sourceExperimental — accuracy not yet measured
The Case discussion reports a cytologic difference: necrotic cells appeared in checkpoint-inhibitor thyroiditis but are not present in autoimmune thyroid disease. It says these features may help explain mechanisms that remain to be elucidated; it does not demonstrate different pathophysiological mechanisms. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Corticosteroid therapy may influence the course of ICPi-induced thyroid dysfunction [57,61].”
§ Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) > 4. Discussion
What the sources say
- Supportedcites [57] Kimbara S. Fujiwara Y. Iwama S. Ohashi K. Kuchiba A. Arima H. Yamazaki N. Kitano S. Yamamoto N. Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab Cancer Sci. 2018 109 3583 3590 10.1111/cas.13800 30230649 PMC6215874 source
The Results section (Onset and timing of TD) reports that thyrotoxicosis did not progress to hypothyroidism in five of six patients given systemic steroids at its onset. The Discussion explicitly suggests that steroid therapy could prevent permanent hypothyroidism, while noting that further investigation is warranted. This supports the citing sentence’s hedged wording. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Yamauchi I. Sakane Y. Fukuda Y. Fujii T. Taura D. Hirata M. Hirota K. Ueda Y. Kanai Y. Yamashita Y. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study Thyroid. 2017 27 894 901 10.1089/thy.2016.0562 28537531 source
hedgedstates a possible causen = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
§ Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) > 4. Discussion
What the sources say
- Partly supportedcites [49] Hodi F.S. O’Day S.J. McDermott D.F. Weber R.W. Sosman J.A. Haanen J.B. Gonzalez R. Robert C. Schadendorf D. Hassel J.C. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma N. Engl. J. Med. 2010 363 711 723 10.1056/NEJMoa1003466 20525992 PMC3549297 sourceExperimental — accuracy not yet measured
The Methods (Patients; page not provided) list autoimmune disease as an exclusion criterion for this ipilimumab trial. The Results (Adverse Events; page not provided) report severe immune-related adverse events, but the paper does not state that heightened susceptibility to those events in patients with pre-existing autoimmune disease was the reason for exclusion. It also does not establish the claim for checkpoint-inhibitor trials generally. (LLM, conf=0.86)
- Partly supportedcites [50] Robert C. Schachter J. Long G.V. Arance A. Grob J.J. Mortier L. Daud A. Carlino M.S. McNeil C. Lotem M. Pembrolizumab versus Ipilimumab in Advanced Melanoma N. Engl. J. Med. 2015 372 2521 2532 10.1056/NEJMoa1503093 25891173 sourceExperimental — accuracy not yet measured
The Patients section (page unavailable) says this trial excluded people with a history of serious autoimmune disease. It does not limit that exclusion to active disease or state that concern about heightened susceptibility to severe immune-related adverse events was the reason. The Adverse Events section (page unavailable) reports immune-related events but does not establish that rationale. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“and that patients who had ICPi-induced hypothyroidism had positive anti-thyroid autoantibodies in 75 to 100% of cases [54,55,56,57].”
§ Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) > 4. Discussion
What the sources say
- Supportedcites [54] Kobayashi T. Iwama S. Yasuda Y. Okada N. Tsunekawa T. Onoue T. Takagi H. Hagiwara D. Ito Y. Morishita Y. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study J. Endocr. Soc. 2018 2 241 251 10.1210/js.2017-00432 29600292 PMC5836529 source
Results §2B identifies three nivolumab-treated patients who developed hypothyroidism (cases 021, 034, and 038). Table 3 shows that all three had positive TPOAb or TgAb levels at some point, yielding 3/3 (100%). Case 034 was antibody-negative at baseline and became positive during treatment, so the 100% figure does not describe baseline positivity. (LLM, conf=0.86)
- Not checked yetcites [55] Maekura T. Naito M. Tahara M. Ikegami N. Kimura Y. Sonobe S. Kobayashi T. Tsuji T. Minomo S. Tamiya A. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer Vivo 2018 31 1035 1039 10.21873/invivo.11166 PMC5656848 28882978 source
Checked before — its earlier verdict is held back until a new check runs.
- Supportedcites [56] Osorio J.C. Ni A. Chaft J.E. Pollina R. Kasler M.K. Stephens D. Rodriguez C. Cambridge L. Rizvi H. Wolchok J.D. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer Ann. Oncol. 2017 28 583 589 10.1093/annonc/mdw640 27998967 PMC5834017 source
The “TSH kinetics and association of thyroid dysfunction with anti-thyroid antibodies” section reports positive antibodies in 8 of 10 patients (80%) who developed thyroid dysfunction during pembrolizumab treatment. These patients required thyroid replacement, and 80% falls within the cited 75–100% range. Page numbers are unavailable in our copy. (LLM, conf=0.90)
- Supportedcites [57] Kimbara S. Fujiwara Y. Iwama S. Ohashi K. Kuchiba A. Arima H. Yamazaki N. Kitano S. Yamamoto N. Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab Cancer Sci. 2018 109 3583 3590 10.1111/cas.13800 30230649 PMC6215874 source
The Discussion reports that antithyroid antibodies were present in 8 of 10 patients (80%) who developed hypothyroidism during pembrolizumab treatment, within the cited 75–100% range. This figure is reported from another study, not from Kimbara's nivolumab cohort. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Two retrospective and two prospective studies reported that positive TPOAb and/or thyroglobulin autoantibodies (TgAb) are associated with a 40 to 70% risk of hypothyroidism during treatment”
§ Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) > 4. Discussion
What the sources say
- Partly supportedcites [54] Kobayashi T. Iwama S. Yasuda Y. Okada N. Tsunekawa T. Onoue T. Takagi H. Hagiwara D. Ito Y. Morishita Y. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study J. Endocr. Soc. 2018 2 241 251 10.1210/js.2017-00432 29600292 PMC5836529 sourceExperimental — accuracy not yet measured
The Results and Discussion (pages unavailable in our copy) report that 3 of 6 antibody-positive patients developed destructive thyroiditis during nivolumab treatment, a 50% incidence. But 50% is the figure for thyroiditis, not hypothyroidism: the Discussion says only three of the four thyroiditis cases progressed to hypothyroidism, and the Results identify one of those cases as antibody-negative. The paper therefore does not support a 40–70% hypothyroidism risk in antibody-positive patients. (LLM, conf=0.87)
- Partly supportedcites [55] Maekura T. Naito M. Tahara M. Ikegami N. Kimura Y. Sonobe S. Kobayashi T. Tsuji T. Minomo S. Tamiya A. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer Vivo 2018 31 1035 1039 10.21873/invivo.11166 PMC5656848 28882978 sourceExperimental — accuracy not yet measured
Our copy is a single retrospective nivolumab study in 64 NSCLC patients; its Abstract and Results state that 'The TPO and thyroglobulin antibodies were significantly positive in patients who developed primary hypothyroidism', and the Discussion/Conclusion hedge that baseline TPOAb and TgAb 'may be predictive of hypothyroidism' (Discussion, p. 1038). That supports the association and the retrospective design, but the paper nowhere reports a '40 to 70%' risk figure, nor does it synthesise two retrospective and two prospective studies; the closest numbers it carries are the antibody-positivity percentages quoted from Alhusseini et al. during the thyroiditis phase (50%, 40%, 40%), which are a different measure. The magnitude and the multi-study attribution are therefore not supported by this source. (LLM, conf=0.75)
- Partly supportedcites [56] Osorio J.C. Ni A. Chaft J.E. Pollina R. Kasler M.K. Stephens D. Rodriguez C. Cambridge L. Rizvi H. Wolchok J.D. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer Ann. Oncol. 2017 28 583 589 10.1093/annonc/mdw640 27998967 PMC5834017 sourceExperimental — accuracy not yet measured
The ‘TSH kinetics and association of thyroid dysfunction with anti-thyroid antibodies’ section reports a strong association during pembrolizumab treatment: antibodies were present in 8 of 10 patients who developed thyroid dysfunction, versus 3 of 38 who did not. But the paper does not report a 40–70% risk of hypothyroidism among antibody-positive patients. Its figures concern thyroid dysfunction in patients with non-small-cell lung cancer, and antibody positivity could arise during treatment rather than being present beforehand. (LLM, conf=0.88)
- Partly supportedcites [57] Kimbara S. Fujiwara Y. Iwama S. Ohashi K. Kuchiba A. Arima H. Yamazaki N. Kitano S. Yamamoto N. Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab Cancer Sci. 2018 109 3583 3590 10.1111/cas.13800 30230649 PMC6215874 sourceExperimental — accuracy not yet measured
The Results section (page not available) reports thyroid dysfunction in 40% of patients with baseline thyroid autoimmunity and 63% of those with TgAb during nivolumab treatment. Those figures are for thyroid dysfunction, which includes thyrotoxicosis, rather than specifically hypothyroidism. TPOAb alone was not significantly associated with thyroid dysfunction; 2 of 16 patients with TPOAb alone developed it. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
29 more claims · 6 with their cited sources checked
Create a free account to see all 68 claims and to verify the 3 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) > Abstract
“The three other patients experienced biphasic thyroiditis with secondary hypothyroidism requiring long-term substitution.”
§ Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) > 3. Results > 3.2. ICPi-Induced Graves’ Disease
“In patients 3 and 5, thyrotoxicosis evolved to hypothyroidism after a few months, requiring long-term substitution of thyroid hormone. Patient 4 died soon after spontaneous evolution towards hypothyroidism”
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 1×
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
BackgroundBrahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · cited 1×
“A recent review of the literature is reassuring on the use of corticosteroids for irAE management, finding that it seems not to reduce overall survival in cancer patients treated with ICPis [62,63] and may be safely administered without compromising outcomes [16,64].”
BackgroundHaanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262 · cited 1×
“A dose-effect is also suggested by a study that used a high dose of Ipilimumab (10 mg/kg), where 10% of patients developed dysthyroidism [14].”
ResultVaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196 · cited 1×
“The range of indications for these treatments has been broadening each year [1].”
BackgroundSafety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · cited 1×
“Note that in the Osorio study [56], survival was better if patients developed ICPi-induced thyroid dysfunction, as suggested by others if there was an occurrence of irAEs [58–60].”
BackgroundEndocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532 · cited 1×
“The hyperthyroid phase typically evolves into hypothyroidism, which may explain many cases of hyperthyroidism being missed in clinical studies [10].”
BackgroundAbdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487 · cited 1×
“However, a growing body of evidence indicates that ICPis may be safe and effective in these patients [51,52].”
BackgroundRyder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439 · cited 1×
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
Backgroundde Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
Dalvin, L. A., Shields, C. L., Orloff, M., Sato, T., & Shields, J. A. (2018) · Retina · doi:10.1097/iae.0000000000002181 · Cited by 336
Ricciuti, B., Dahlberg, S. E., Adeni, A., Sholl, L. M., Nishino, M., & Awad, M. M. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00189 · Cited by 333 · cited 1×
“A recent review of the literature is reassuring on the use of corticosteroids for irAE management, finding that it seems not to reduce overall survival in cancer patients treated with ICPis [62,63] and may be safely administered without compromising outcomes [16,64].”
BackgroundDanlos, F.-X., Voisin, A.-L., Dyevre, V., Michot, J.-M., Routier, E., Taillade, L., Champiat, S., Aspeslagh, S., Haroche, J., Albiges, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.008 · Cited by 300 · cited 1×
“Nonetheless, a pre-existing AID was associated with a significantly increased risk of irAEs [53].”
BackgroundSelf-citationPetrelli, F., Signorelli, D., Ghidini, M., Ghidini, A., Pizzutilo, E. G., Ruggieri, L., Cabiddu, M., Borgonovo, K., Dognini, G., Brighenti, M., et al. (2020) · Cancers · doi:10.3390/cancers12030546 · Cited by 300 · cited 2×
“A recent review of the literature is reassuring on the use of corticosteroids for irAE management, finding that it seems not to reduce overall survival in cancer patients treated with ICPis [62,63] and may be safely administered without compromising outcomes [16,64].”
BackgroundDelivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
Arnaud‐Coffin, P., Maillet, D., Gan, H. K., Stelmes, J., You, B., Dalle, S., & Péron, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32132 · Cited by 255 · cited 1×
“However, by inhibiting negative regulators of adaptive immunity, ICPis may also trigger immune-related adverse events (irAE) involving different organs, with a frequency of 14% of grade 3 and 4 irAE observed with anti-PD-(L)1 treatment, 34% with anti-CTLA-4 treatment, and 55% with combined immunotherapy [2].”
BackgroundSelf-citationIncidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244 · cited 1×
“Graves’ hyperthyroidism De Filette, 2016 [19] anti-PD-1 (Pembrolizumab) 2 mg/kg/na na na/na Yes No na na/na Positive (na) Negative na na na No Yes”
BackgroundHaanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M. N., Whitelaw, B. C., Palomar, M. T. P., Wu, Y., & Carroll, P. V. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 220 · cited 1×
“Thyroid dysfunctions (TDs) generally appear during the first weeks of ICPi treatment, although they may in some cases be delayed [7,11,12].”
BackgroundKobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Tsunekawa, T., Onoue, T., Takagi, H., Hagiwara, D., Ito, Y., Morishita, Y., et al. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2017-00432 · Cited by 203
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190 · cited 3×
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
BackgroundGraves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy
Antonelli, A., Fallahi, P., Elia, G., Ragusa, F., Paparo, S. R., Ruffilli, I., Patrizio, A., Gonnella, D., Giusti, C., Virili, C., et al. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101388 · Cited by 190
Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease
Lazarus, J. H. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.005 · Cited by 182
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179 · cited 1×
“Min, 2011 [30] anti-CTLA-4 (Ipilimumab) 10 mg/kg/3 weeks F 51 No/na No Yes IV/12 weeks 1/na Positive (1.”
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Yamauchi, I., Sakane, Y., Fukuda, Y., Fujii, T., Taura, D., Hirata, M., Hirota, K., Ueda, Y., Kanai, Y., Yamashita, Y., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0562 · Cited by 169 · cited 1×
“Corticosteroid therapy may influence the course of ICPi-induced thyroid dysfunction [57,61].”
BackgroundThe Genetics of Autoimmune Thyroid Disease
Vaidya, B., Kendall-Taylor, P., & Pearce, S. H. S. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020492 · Cited by 164
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Lee, H., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Buchbinder, E. I., Haq, R., Tolaney, S., Barroso-Sousa, R., Zhang, K., Donahue, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0208 · Cited by 161
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158 · cited 2×
“noted that of 20 patients with induced thyrotoxicosis, five of the six who did not develop secondary hypothyroidism had received corticosteroid therapy for another reason [57].”
BackgroundDaniels, G. H., Vladic, A., Brinar, V., Zavalishin, I., Valente, W., Oyuela, P., Palmer, J., & Margolin, D. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2201 · Cited by 150
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
Self-citationEndocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 136 · cited 1×
“The endocrine irAEs involve several endocrine glands (pituitary, thyroid, adrenals, and pancreas) [3].”
BackgroundOrlov, S., Salari, F., Kashat, L., & Walfish, P. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4560 · Cited by 134 · cited 1×
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
BackgroundDrug-Induced Graves Disease From CTLA-4 Receptor Suppression
Borodic, G., Hinkle, D. M., & Cia, Y. (2011) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0b013e3181ef72a1 · Cited by 120
Barroso‐Sousa, R., Ott, P. A., Hodi, F. S., Kaiser, U. B., Tolaney, S. M., & Min, L. (2018) · Cancer · doi:10.1002/cncr.31200 · Cited by 113
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93 · cited 1×
“McElnea, 2014 [29] anti-CTLA-4 (Ipilimumab) 3 mg/kg/2 weeks F 68 No/No No Yes III/6 weeks 1/na Negative Negative na na na GC (na) No”
BackgroundSagiv, O., Kandl, T. J., Thakar, S. D., Thuro, B. A., Busaidy, N. L., Cabanillas, M., Jimenez, C., Dadu, R., Graham, P. H., Debnam, J. M., et al. (2019) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0000000000001161 · Cited by 71 · cited 5×
“and was treated with glucocorticoids, and hyperthyroidism resolved spontaneously [42].”
BackgroundInfluentialAngell, T. E., Min, L., Wieczorek, T. J., & Hodi, F. S. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2017.11.002 · Cited by 69 · cited 1×
“Histological and morphological analysis can demonstrate different pathophysiological mechanisms between autoimmune and ICPi-induced thyrotoxicosis [26,27].”
BackgroundGraves’ Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature
Brancatella, A., Viola, N., Brogioni, S., Montanelli, L., Sardella, C., Vitti, P., Marcocci, C., Lupi, I., & Latrofa, F. (2019) · European Thyroid Journal · doi:10.1159/000501824 · Cited by 69 · cited 1×
“Brancatella, 2019 [37] anti-PD-1 (Nivolumab) 3 mg/kg/ 2 weeks M 51 na/na Yes No IV/8 weeks 1.”
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/l18-0209 · Cited by 63
Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma
Azmat, U., Liebner, D., Joehlin-Price, A., Agrawal, A., & Nabhan, F. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/2087525 · Cited by 59 · cited 1×
“Azmat, 2016 [35] anti-CTLA-4 (Ipilimumab) 3 mg/kg/2 weeks M 67 No/na Yes No II/6 weeks 2.”
Tremelimumab-Induced Graves Hyperthyroidism
Gan, E. H., Mitchell, A. L., Plummer, R., Pearce, S., & Perros, P. (2017) · European Thyroid Journal · doi:10.1159/000464285 · Cited by 58
Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
(2018) · In Vivo · doi:10.21873/invivo.11166 · Cited by 51
Autoimmunity and Graves’ Disease
Bahn, R. S. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.10 · Cited by 49
Levy, M., Abeillon, J., Dalle, S., Assaad, S., Borson‐Chazot, F., Disse, E., Raverot, G., & Cugnet‐Anceau, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103280 · Cited by 46 · cited 1×
“Patients included were referred either by dermatologists, respiratory physicians, or oncologists for thyrotoxicosis during ICPi treatment, from December 2015 to December 2020, through the ImmuCare and Tox’imm networks (healthcare networks in Lyon including patients who have presented irAEs due to ICPis during treatmen…”
BackgroundSelf-citationSevere Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment
Campredon, P., Imbert, P., Mouly, C., Grunenwald, S., Mazières, J., & Caron, P. (2018) · European Thyroid Journal · doi:10.1159/000485742 · Cited by 42 · cited 1×
“Campredon, 2018 [44] anti-PD-1 (Nivolumab) na M 61 No/No No Yes III/6 weeks 1/1 Negative Negative na na na GC (na) No”
BackgroundShang, Y. H., Zhang, Y., Li, J. H., Li, P., & Zhang, X. (2017) · Immunotherapy · doi:10.2217/imt-2016-0147 · Cited by 39
Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis
Iadarola, C., Croce, L., Quaquarini, E., Teragni, C., Pinto, S., Bernardo, A., Fonte, R., Marinò, M., Rotondi, M., & Chiovato, L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00813 · Cited by 33 · cited 1×
“Iadarola, 2019 [39] anti-PD-1 (Nivolumab) 3 mg/kg/ 2 weeks F 66 na/na Yes No II/4 weeks 1/1.”
Diagnostic procedure in suspected Graves’ disease
Goichot, B., Leenhardt, L., Massart, C., Raverot, V., Tramalloni, J., & Iraqi, H. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.08.002 · Cited by 32
Ni, J., Qiu, L.-J., Zhang, M., Wen, P.-F., Ye, X.-R., Liang, Y., Pan, H.-F., & Ye, D.-Q. (2014) · Endocrine Research · doi:10.3109/07435800.2013.879167 · Cited by 28
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
(2017) · In Vivo · doi:10.21873/invivo.11195 · Cited by 28 · cited 1×
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
BackgroundPatel, N. S., Oury, A., Daniels, G. A., Bazhenova, L., & Patel, S. P. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0375 · Cited by 25 · cited 3×
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
BackgroundKurihara, S., Oikawa, Y., Nakajima, R., Satomura, A., Tanaka, R., Kagamu, H., & Shimada, A. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13212 · Cited by 24 · cited 1×
“Kurihara, 2020 [41] anti-PD-1 (Nivolumab) 240 mg/2–5 weeks M 48 No/No Yes No VI/16 weeks 1.”
A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy
Park, E. S., Rabinowits, G., Hamnvik, O. R., & Dagi, L. R. (2018) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2018.01.006 · Cited by 22 · cited 1×
“Park, 2018 [43] anti-PD-1 (Pembrolizumab) 1 cycle/2 weeks M 52 No/Yes (g) No Yes III/9 weeks na/na na na na na na GC (na) No”
BackgroundTorimoto, K., Okada, Y., Nakayamada, S., Kubo, S., & Tanaka, Y. (2017) · Thyroid · doi:10.1089/thy.2017.0062 · Cited by 20 · cited 1×
“Histological and morphological analysis can demonstrate different pathophysiological mechanisms between autoimmune and ICPi-induced thyrotoxicosis [26,27].”
BackgroundYamada, H., Okajima, F., Onda, T., Fujimori, S., Emoto, N., & Sugihara, H. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00613-5 · Cited by 17 · cited 1×
“Yamada, 2020 [40] anti-PD-1 (Nivolumab) 240 mg/3 weeks M 66 No/No Yes No II/6 weeks >2.”
Yajima, K., & Akise, Y. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/2314032 · Cited by 13 · cited 1×
“Yajima, 2019 [38] anti-PD-1 (Pembrolizumab) 200 mg/3 weeks M 61 No/No Yes No V/14 weeks 2.”
Les dysthyroïdies sous immunothérapie anti-cancéreuse
Anceau, C. C., Abeillon, J., Maillet, D., Borson‐Chazot, F., & Disse, E. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.10.005 · Cited by 11
Self-citation
Cited by
Dwivedi, S. N., Kalaria, T., & Buch, H. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208290 · Cited by 91
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 67
Endocrine side effects of immune checkpoint inhibitors
Cardona, Z., Sosman, J. A., Chandra, S., & Huang, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1157805 · Cited by 63
Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction
Zhang, Q., Jiao, X., & Lai, X. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad260 · Cited by 31
Percik, R., Criseno, S., Adam, S., Young, K., & Morganstein, D. L. (2023) · Endocrine Connections · doi:10.1530/ec-22-0513 · Cited by 35
Metadata
- Authors
- Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J.
- Affiliations
- Lyon 1 Université (FR)
- Service d’Endocrinologie-Diabète-Nutrition, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre-Bénite, France
- Faculté de Médecine, Université Lyon 1, 69008 Lyon, France
- Centre Léon Bérard (FR)
- Fédération d’Endocrinologie, Hôpital Louis Pradel, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500 Bron, France
- Corresponding author
- Peiffert, Mathilde
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-04-17
- Volume
- 13
- Issue
- 8
- Pages
- 1944
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8073133
- OpenAlex
- W3156514035
- Semantic Scholar
- fb8f92b79dd658eabce3ac01aff634dba7ba820d
- Cited by
- 33
- References
- 67
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 3 · 2023: 9 · 2022: 11 · 2021: 3
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Keywords
- Graves' disease, immune checkpoint inhibitors, immune-related adverse events, thyrotoxicosis, TSH receptor antibodies, central hypothyroidism, antithyroid drugs, Graves' ophthalmopathy, thyroid scintigraphy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.